Ubiquitin-Proteasome System: Promising Therapeutic Targets in Autoimmune and Neurodegenerative Diseases

[1]  Robert H. Brown,et al.  CCNF mutations in amyotrophic lateral sclerosis and frontotemporal dementia , 2016, Nature Communications.

[2]  A. Ciulli,et al.  Serendipitous SAD Solution for DMSO-Soaked SOCS2-ElonginC-ElonginB Crystals Using Covalently Incorporated Dimethylarsenic: Insights into Substrate Receptor Conformational Flexibility in Cullin RING Ligases , 2015, PloS one.

[3]  A. Ciulli,et al.  Targeting Cullin–RING E3 ubiquitin ligases for drug discovery: structure, assembly and small-molecule modulation , 2015, The Biochemical journal.

[4]  T. Spector,et al.  Effect of UBE2L3 genotype on regulation of the linear ubiquitin chain assembly complex in systemic lupus erythematosus , 2015, The Lancet.

[5]  T. Spector,et al.  UBE2L3 Polymorphism Amplifies NF-κB Activation and Promotes Plasma Cell Development, Linking Linear Ubiquitination to Multiple Autoimmune Diseases , 2015, American journal of human genetics.

[6]  W. Lems,et al.  Proteasome inhibitors as experimental therapeutics of autoimmune diseases , 2015, Arthritis Research & Therapy.

[7]  N. Jha,et al.  Tau phosphorylation, molecular chaperones, and ubiquitin E3 ligase: clinical relevance in Alzheimer's disease. , 2014, Journal of Alzheimer's disease : JAD.

[8]  P. Grandi,et al.  Biophysical Studies on Interactions and Assembly of Full-size E 3 Ubiquitin Ligase SUPPRESSOR OF CYTOKINE SIGNALING 2 ( SOCS 2 )-ELONGIN BC-CULLIN 5-RING BOX PROTEIN 2 ( RBX 2 ) * , 2015 .

[9]  V. Negi,et al.  Immunoglobulin-like transcripts 6 (ILT6) polymorphism influences the anti-Ro60/52 autoantibody status in south Indian SLE patients , 2014, Lupus.

[10]  Steven P. Gygi,et al.  Landscape of the PARKIN-dependent ubiquitylome in response to mitochondrial depolarization , 2013, Nature.

[11]  K. Ozato,et al.  Autoantigen TRIM21/Ro52 as a Possible Target for Treatment of Systemic Lupus Erythematosus , 2012, International journal of rheumatology.

[12]  Y. Shintani,et al.  FBL2 Regulates Amyloid Precursor Protein (APP) Metabolism by Promoting Ubiquitination-Dependent APP Degradation and Inhibition of APP Endocytosis , 2012, The Journal of Neuroscience.

[13]  G. Schett,et al.  Refractory SLE patients respond to the proteasome inhibitor bortezomib , 2012 .

[14]  T. Muchamuel,et al.  Beneficial effect of novel proteasome inhibitors in murine lupus via dual inhibition of type I interferon and autoantibody-secreting cells. , 2012, Arthritis and rheumatism.

[15]  Y. Nomura,et al.  Molecular approaches to the treatment, prophylaxis, and diagnosis of Alzheimer's disease: possible involvement of HRD1, a novel molecule related to endoplasmic reticulum stress, in Alzheimer's disease. , 2012, Journal of pharmacological sciences.

[16]  G. van Loo,et al.  Genetic relationships between A20/TNFAIP3, chronic inflammation and autoimmune disease. , 2011, Biochemical Society transactions.

[17]  P. Gregersen,et al.  Association of a functional variant downstream of TNFAIP3 with systemic lupus erythematosus , 2011, Nature Genetics.

[18]  H. Anders,et al.  Mdm 2 Promotes Systemic Lupus Erythematosus and Lupus Nephritis , 2011 .

[19]  Rudi Beyaert,et al.  Expression, biological activities and mechanisms of action of A20 (TNFAIP3). , 2010, Biochemical pharmacology.

[20]  C. Liu,et al.  The ubiquitin modifying enzyme A20 restricts B cell survival and prevents autoimmunity. , 2010, Immunity.

[21]  N. Hattori,et al.  PINK1 stabilized by mitochondrial depolarization recruits Parkin to damaged mitochondria and activates latent Parkin for mitophagy , 2010, The Journal of cell biology.

[22]  R. Youle,et al.  Parkin is recruited selectively to impaired mitochondria and promotes their autophagy , 2008, The Journal of cell biology.

[23]  David Altshuler,et al.  Genetic variants near TNFAIP3 on 6q23 are associated with systemic lupus erythematosus , 2008, Nature Genetics.

[24]  Hiderou Yoshida,et al.  ER stress and diseases , 2007, The FEBS journal.